Evidence map›Paper›PMID 38901674›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2024

Expression of L1 Cell Adhesion Molecule, a Nephronal Principal Cell Marker, in Nephrogenic Adenoma.

Rahul Mannan, Xiaoming Wang, Somnath Mahapatra, Susanna Wang, Anya K Chinnaiyan, Stephanie L Skala, Yuping Zhang, Lisa M McMurry, Sylvia Zelenka-Wang, Xuhong Cao and 8 more

Abstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rahul MannanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, Ann Arbor, Michigan.
Xiaoming WangDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, Ann Arbor, Michigan.
Somnath MahapatraDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, Ann Arbor, Michigan.
Susanna WangMichigan Center for Translational Pathology, Ann Arbor, Michigan.
Anya K ChinnaiyanMichigan Center for Translational Pathology, Ann Arbor, Michigan.
Stephanie L SkalaDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Rogel Cancer Center, Michigan Medicine, Ann Arbor, Michigan.
Yuping ZhangDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, Ann Arbor, Michigan.
Lisa M McMurryDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, Ann Arbor, Michigan.
Sylvia Zelenka-WangDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, Ann Arbor, Michigan.
Xuhong CaoMichigan Center for Translational Pathology, Ann Arbor, Michigan; Howard Hughes Medical Institute, Ann Arbor, Michigan.
Ankur R SangoiDepartment of Pathology, School of Medicine, Stanford Medicine, California.
Vipulkumar DadhaniaDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.
Maria M PickenDepartment of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, Illinois.
Santosh MenonDepartment of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Hikmat Al-AhmadieDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Arul M ChinnaiyanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, Ann Arbor, Michigan; Rogel Cancer Center, Michigan Medicine, Ann Arbor, Michigan; Howard Hughes Medical Institute, Ann Arbor, Michigan; Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan.
Saravana M DhanasekaranDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, Ann Arbor, Michigan.
Rohit MehraDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, Ann Arbor, Michigan; Rogel Cancer Center, Michigan Medicine, Ann Arbor, Michigan. Electronic address: mrohit@med.umich.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Exploring Precision Oncology: From Gene Fusions to lncRNAsR35CA231996 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2018 to 2024
$6.4M
Michigan-VUMC Biomarker Characterization CenterU2CCA271854 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ARUL M CHINNAIYAN · 2022 to 2026
$5.4M
NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA231996NCI NIH HHS U2C CA271854
6 · The paper itself

Abstract

Nephrogenic adenoma (NA) is a benign, reactive lesion seen predominantly in the urinary bladder and often associated with antecedent inflammation, instrumentation, or an operative history. Its histopathologic diversity can create diagnostic dilemmas and pathologists use morphologic evaluation along with available immunohistochemical (IHC) markers to navigate these challenges. IHC assays currently do not designate or specify NA's potential putative cell of origin. Leveraging single-cell RNA-sequencing technology, we nominated a principal (P) cell-collecting duct marker, L1 cell adhesion molecule (L1CAM), as a potential biomarker for NA. IHC characterization revealed L1CAM to be positive in all 35 (100%) patient samples of NA; negative expression was seen in the benign urothelium, benign prostatic glands, urothelial carcinoma (UCA) in situ, prostatic adenocarcinoma, majority of high-grade UCA, and metastatic UCA. In the study, we also used single-cell RNA sequencing to nominate a novel compendium of biomarkers specific for the proximal tubule, loop of Henle, and distal tubule (DT) (including P and intercalated cells), which can be used to perform nephronal mapping using RNA in situ hybridization and IHC technology. Employing this technique on NA we found enrichment of both the P-cell marker L1CAM and, the proximal tubule type-A and -B cell markers, PDZKI1P1 and PIGR, respectively. The cell-type markers for the intercalated cell of DTs (LINC01187 and FOXI1), and the loop of Henle (UMOD and IRX5), were found to be uniformly absent in NA. Overall, our findings show that based on cell type-specific implications of L1CAM expression, the shared expression pattern of L1CAM between DT P cells and NA. L1CAM expression will be of potential value in assisting surgical pathologists toward a diagnosis of NA in challenging patient samples.

Indexed as

AdenomaBiomarkers, TumorNeural Cell Adhesion Molecule L1AdultAgedFemaleHumansImmunohistochemistryMaleMiddle AgedNephronsUrinary Bladder NeoplasmsBiomarkers, TumorL1CAM protein, humanNeural Cell Adhesion Molecule L1cell type–specific markerimmunohistochemistrykidneyL1CAMnephrogenic adenomaurothelial carcinoma

Identifiers

PMID38901674
PMCPMC11344683

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.